Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pilot study of pirfenidone for COVID-19-related acute respiratory distress syndrome
MOH_2020-09-24_009072Phase 2Not yet recruiting
- Sponsor
- ד"ר אורי גלנטה
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pirfenidone in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by ד"ר אורי גלנטה. Primary endpoint: Safety and efficacy of pirfenidone. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
pirfenidone
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on MOH_2020-09-24_009072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-24_009072.